Recent Updates
Recently added Catalysts

ABBV-637

Phase 1

Advanced Solid Tumors Cancer | Small molecule | Oncology |AbbVie Inc.|Last Updated: Jul 3, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDBiomarker
Total Trials1
Total Enrollment81
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid TumorsPHASE1 ACTIVE NOT_RECRUITING 81Feb 23, 2021Feb 1, 2026Jul 3, 202533 United States, Australia +6
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Experiencing Adverse Events (AEs)
Up to approximately 3 years

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

Percentage of Participants With Objective Response Rate (ORR) (Part 2 & 3)
Up to approximately 3 years

ORR is defined as the percentage of participants with a confirmed response (CR) or partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Secondary Endpoints
Percentage of Participants With Objective Response Rate (ORR) (Part 1)
Up to approximately 3 years
Duration of Response (DOR) for ABBV-637 Administered as Monotherapy (Part 1)
Up to approximately 12 months
Duration of Response (DOR) for ABBV-637 in Combination With Docetaxel and Osimertinib (Part 2 & 3)
Up to approximately 20 months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part 1: ABBV-637 MonotherapyEXPERIMENTALParticipants will receive escalating doses of ABBV-637 in 28-day cycles.
Part 2a: ABBV-637 + DocetaxelEXPERIMENTALParticipants will receive escalating doses of ABBV-637 in combination with docetaxel in 28-day cycles.
Part 2b: ABBV-637 + DocetaxelEXPERIMENTALParticipants will receive ABBV-637 at dose determined in Part 2a in combination with docetaxel in 28-day cycles.
Part 3a: ABBV-637 + OsimertinibEXPERIMENTALParticipants will receive escalating doses of ABBV-637 in combination with osimertinib in 28-day cycles.
Part 3b: ABBV-637 + OsimertinibEXPERIMENTALParticipants will receive ABBV-637 at dose determined in Part 3a in combination with osimertinib in 28-day cycles.
Interventions
NameTypeDescription
ABBV-637DRUGIntravenous (IV) Infusion
DocetaxelDRUGIntravenous (IV) Infusion
OsimertinibDRUGOral Tablets
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites33

Inclusion Criteria: * Histologic solid tumor diagnosis (Part 1). * For Part 2 docetaxel combination therapy: EGFR WT expressing relapsed/refractory (R/R) non-small cell lung cancer (NSCLC) participants. * For Part 3 osimertinib combination therapy: mutEGFR-expressing RR NSCLC participants. * Measur...

Countries:United StatesAustraliaFranceIsraelJapanSouth KoreaSpainTaiwan
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT04721015primaryCompletionDate: changed
LOWMay 24, 2026NCT04721015studyFirstPostDate: changed